Cadrenal Therapeutics (CVKD) Competitors $12.26 -0.24 (-1.92%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$11.76 -0.50 (-4.07%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CVKD vs. JSPR, CTNM, COYA, TNYA, IOBT, VXRT, OPTN, SAVA, XBIT, and CRBPShould you be buying Cadrenal Therapeutics stock or one of its competitors? The main competitors of Cadrenal Therapeutics include Jasper Therapeutics (JSPR), Contineum Therapeutics (CTNM), Coya Therapeutics (COYA), Tenaya Therapeutics (TNYA), IO Biotech (IOBT), Vaxart (VXRT), OptiNose (OPTN), Cassava Sciences (SAVA), XBiotech (XBIT), and Corbus Pharmaceuticals (CRBP). These companies are all part of the "pharmaceutical products" industry. Cadrenal Therapeutics vs. Its Competitors Jasper Therapeutics Contineum Therapeutics Coya Therapeutics Tenaya Therapeutics IO Biotech Vaxart OptiNose Cassava Sciences XBiotech Corbus Pharmaceuticals Jasper Therapeutics (NASDAQ:JSPR) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations. Which has more risk and volatility, JSPR or CVKD? Jasper Therapeutics has a beta of 2.69, indicating that its stock price is 169% more volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Which has preferable earnings and valuation, JSPR or CVKD? Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJasper TherapeuticsN/AN/A-$71.27M-$5.24-0.63Cadrenal TherapeuticsN/AN/A-$10.65M-$9.26-1.32 Is JSPR or CVKD more profitable? Jasper Therapeutics' return on equity of -109.45% beat Cadrenal Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Jasper TherapeuticsN/A -109.45% -89.82% Cadrenal Therapeutics N/A -244.94%-181.94% Do analysts prefer JSPR or CVKD? Jasper Therapeutics currently has a consensus price target of $29.75, suggesting a potential upside of 798.79%. Cadrenal Therapeutics has a consensus price target of $32.00, suggesting a potential upside of 161.01%. Given Jasper Therapeutics' higher probable upside, equities analysts clearly believe Jasper Therapeutics is more favorable than Cadrenal Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jasper Therapeutics 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60Cadrenal Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to JSPR or CVKD? In the previous week, Jasper Therapeutics had 18 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 19 mentions for Jasper Therapeutics and 1 mentions for Cadrenal Therapeutics. Cadrenal Therapeutics' average media sentiment score of 1.87 beat Jasper Therapeutics' score of 0.22 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Jasper Therapeutics Neutral Cadrenal Therapeutics Very Positive Do insiders and institutionals hold more shares of JSPR or CVKD? 79.9% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 4.6% of Jasper Therapeutics shares are owned by company insiders. Comparatively, 48.6% of Cadrenal Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryJasper Therapeutics beats Cadrenal Therapeutics on 9 of the 13 factors compared between the two stocks. Get Cadrenal Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CVKD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CVKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVKD vs. The Competition Export to ExcelMetricCadrenal TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.58M$2.96B$5.61B$9.29BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-1.3220.2228.5419.58Price / SalesN/A298.23430.1194.56Price / CashN/A43.1536.0257.93Price / Book2.947.568.145.54Net Income-$10.65M-$55.11M$3.24B$257.73M7 Day Performance-5.47%3.81%0.17%-0.08%1 Month Performance-10.51%11.60%5.95%8.09%1 Year PerformanceN/A-2.11%26.22%13.02% Cadrenal Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVKDCadrenal Therapeutics2.9338 of 5 stars$12.26-1.9%$32.00+161.0%N/A$24.58MN/A-1.324Positive NewsJSPRJasper Therapeutics3.6611 of 5 stars$3.04-55.1%$48.00+1,478.9%-83.4%$101.70MN/A-0.5820Analyst RevisionHigh Trading VolumeCTNMContineum Therapeutics3.65 of 5 stars$3.81-1.8%$22.50+490.6%-82.0%$100.38M$50M-1.9331News CoveragePositive NewsCOYACoya Therapeutics1.9444 of 5 stars$5.87-1.5%$16.67+183.9%-21.4%$99.68M$3.69M-5.496TNYATenaya Therapeutics3.4 of 5 stars$0.58-4.7%$6.25+971.5%-80.4%$99.54MN/A-0.50110IOBTIO Biotech3.624 of 5 stars$1.43-4.0%$9.33+552.7%+23.2%$98.16MN/A-0.9630VXRTVaxart3.3306 of 5 stars$0.32-25.1%$3.00+837.5%-44.8%$97.49M$28.70M-1.19120Positive NewsGap DownHigh Trading VolumeOPTNOptiNose0.6619 of 5 stars$9.60flat$9.00-6.3%N/A$97.22M$81.86M-2.29190SAVACassava Sciences4.272 of 5 stars$1.93-4.0%$54.50+2,723.8%-83.3%$97.10MN/A-1.2930Positive NewsXBITXBiotech1.9166 of 5 stars$3.05-4.1%N/A-56.3%$96.95M$4.01M-2.36100News CoverageCRBPCorbus Pharmaceuticals4.2975 of 5 stars$7.30-5.3%$50.88+596.9%-86.4%$94.35MN/A-1.7340News Coverage Related Companies and Tools Related Companies JSPR Competitors CTNM Competitors COYA Competitors TNYA Competitors IOBT Competitors VXRT Competitors OPTN Competitors SAVA Competitors XBIT Competitors CRBP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CVKD) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAll New Social Security Numbers coming July 23?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadrenal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cadrenal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
